Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.
Protective autoimmunity (PA) is a physiological response to central nervous system trauma that has demonstrated to promote neuroprotection after spinal cord injury (SCI). To reach its beneficial effect, PA should be boosted by immunizing with neural constituents or neural-derived peptides such as A9...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3279414?pdf=render |
id |
doaj-16c876e6e5d449fcb7342f1a91a1c224 |
---|---|
record_format |
Article |
spelling |
doaj-16c876e6e5d449fcb7342f1a91a1c2242020-11-24T21:34:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0172e3202710.1371/journal.pone.0032027Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.Susana MartiñónElisa GarcíaGabriel Gutierrez-OspinaHumberto MestreAntonio IbarraProtective autoimmunity (PA) is a physiological response to central nervous system trauma that has demonstrated to promote neuroprotection after spinal cord injury (SCI). To reach its beneficial effect, PA should be boosted by immunizing with neural constituents or neural-derived peptides such as A91. Immunizing with A91 has shown to promote neuroprotection after SCI and its use has proven to be feasible in a clinical setting. The broad applications of neural-derived peptides make it important to determine the main features of this anti-A91 response. For this purpose, adult Sprague-Dawley rats were subjected to a spinal cord contusion (SCC; moderate or severe) or a spinal cord transection (SCT; complete or incomplete). Immediately after injury, animals were immunized with PBS or A91. Motor recovery, T cell-specific response against A91 and the levels of IL-4, IFN-γ and brain-derived neurotrophic factor (BDNF) released by A91-specific T (T(A91)) cells were evaluated. Rats with moderate SCC, presented a better motor recovery after A91 immunization. Animals with moderate SCC or incomplete SCT showed significant T cell proliferation against A91 that was characterized chiefly by the predominant production of IL-4 and the release of BDNF. In contrast, immunization with A91 did not promote a better motor recovery in animals with severe SCC or complete SCT. In fact, T cell proliferation against A91 was diminished in these animals. The present results suggest that the effective development of PA and, consequently, the beneficial effects of immunizing with A91 significantly depend on the severity of SCI. This could mainly be attributed to the lack of T(A91) cells which predominantly showed to have a Th2 phenotype capable of producing BDNF, further promoting neuroprotection.http://europepmc.org/articles/PMC3279414?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Susana Martiñón Elisa García Gabriel Gutierrez-Ospina Humberto Mestre Antonio Ibarra |
spellingShingle |
Susana Martiñón Elisa García Gabriel Gutierrez-Ospina Humberto Mestre Antonio Ibarra Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury. PLoS ONE |
author_facet |
Susana Martiñón Elisa García Gabriel Gutierrez-Ospina Humberto Mestre Antonio Ibarra |
author_sort |
Susana Martiñón |
title |
Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury. |
title_short |
Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury. |
title_full |
Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury. |
title_fullStr |
Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury. |
title_full_unstemmed |
Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury. |
title_sort |
development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
Protective autoimmunity (PA) is a physiological response to central nervous system trauma that has demonstrated to promote neuroprotection after spinal cord injury (SCI). To reach its beneficial effect, PA should be boosted by immunizing with neural constituents or neural-derived peptides such as A91. Immunizing with A91 has shown to promote neuroprotection after SCI and its use has proven to be feasible in a clinical setting. The broad applications of neural-derived peptides make it important to determine the main features of this anti-A91 response. For this purpose, adult Sprague-Dawley rats were subjected to a spinal cord contusion (SCC; moderate or severe) or a spinal cord transection (SCT; complete or incomplete). Immediately after injury, animals were immunized with PBS or A91. Motor recovery, T cell-specific response against A91 and the levels of IL-4, IFN-γ and brain-derived neurotrophic factor (BDNF) released by A91-specific T (T(A91)) cells were evaluated. Rats with moderate SCC, presented a better motor recovery after A91 immunization. Animals with moderate SCC or incomplete SCT showed significant T cell proliferation against A91 that was characterized chiefly by the predominant production of IL-4 and the release of BDNF. In contrast, immunization with A91 did not promote a better motor recovery in animals with severe SCC or complete SCT. In fact, T cell proliferation against A91 was diminished in these animals. The present results suggest that the effective development of PA and, consequently, the beneficial effects of immunizing with A91 significantly depend on the severity of SCI. This could mainly be attributed to the lack of T(A91) cells which predominantly showed to have a Th2 phenotype capable of producing BDNF, further promoting neuroprotection. |
url |
http://europepmc.org/articles/PMC3279414?pdf=render |
work_keys_str_mv |
AT susanamartinon developmentofprotectiveautoimmunitybyimmunizationwithaneuralderivedpeptideisineffectiveinseverespinalcordinjury AT elisagarcia developmentofprotectiveautoimmunitybyimmunizationwithaneuralderivedpeptideisineffectiveinseverespinalcordinjury AT gabrielgutierrezospina developmentofprotectiveautoimmunitybyimmunizationwithaneuralderivedpeptideisineffectiveinseverespinalcordinjury AT humbertomestre developmentofprotectiveautoimmunitybyimmunizationwithaneuralderivedpeptideisineffectiveinseverespinalcordinjury AT antonioibarra developmentofprotectiveautoimmunitybyimmunizationwithaneuralderivedpeptideisineffectiveinseverespinalcordinjury |
_version_ |
1725948725679882240 |